全髋与膝关节置换术后延长口服氨甲环酸改善患者报告结局
回顾性队列研究纳入312例初次全髋/膝关节置换患者,比较术后延长口服氨甲环酸三天与历史对照。延长组患者报告结局改善更显著(27.7 vs 18.1,P<0.001),置换相关急诊就诊减少(OR 0.11,95%CI 0.02-0.49,P=0.007),住院时长、90天再入院及并发症无显著差异。
要点
- 术后口服氨甲环酸三天与患者报告功能改善更显著相关。
- 延长用药与置换相关急诊就诊减少相关,OR 0.11(95%CI 0.02-0.49)。
- 住院时长、90天再入院及并发症(含感染、血栓事件)无显著差异。
核心结论
- 初次全髋和膝关节置换术后口服氨甲环酸三天与早期患者报告功能改善相关,且不增加并发症或住院时长。
研究设计与样本
- 单中心回顾性队列研究,纳入312例初次全髋/膝关节置换患者(口服氨甲环酸组153例,历史对照组159例),至少随访三个月。
- 所有患者术前和关切口时接受标准1克静脉氨甲环酸;口服组自手术当天起额外口服1.95克氨甲环酸并持续三天。
主要发现
- 延长口服氨甲环酸组患者报告结局改善显著大于对照组(变化27.7 vs 18.1,P<0.001)。
- 延长口服氨甲环酸组置换相关急诊就诊显著减少(OR 0.11,95%CI 0.02-0.49,P=0.007)。
- 住院时长、90天再入院及术后并发症(包括感染或血栓栓塞事件)组间无显著差异(所有P>0.05)。
关键数值与推荐
- 患者报告结局改善:口服氨甲环酸组变化27.7,历史对照组变化18.1(P<0.001)。
- 置换相关急诊就诊:OR 0.11(95%CI 0.02-0.49,P=0.007)。
临床怎么用
- 在初次全髋和膝关节置换术后可考虑延长口服氨甲环酸三天以改善早期患者报告功能并减少置换相关急诊就诊。
- 该方案未增加住院时长、90天再入院及并发症风险,但需结合患者个体情况评估。
局限性
- 回顾性队列设计,与历史对照组比较,可能存在选择偏倚和未测量混杂因素。
- 单中心研究,样本量有限(共312例),随访至少三个月,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tranexamic acid (TXA) is widely used in total joint arthroplasty (TJA) to reduce perioperative blood loss and transfusion requirements. There is a growing body of literature on the use of extended postoperative TXA following total knee arthroplasty (TKA). This study evaluated the impact of an extended postoperative oral TXA regimen following total hip arthroplasty (THA) and TKA. METHODS: After obtaining Institutional Review Board approval, a retrospective chart review was conducted to identify patients who underwent THA/TKA at a single institution. All patients received a standard 1-gram intravenous TXA dose prior to incision and at the time of closure. Those who underwent TJA after formal adoption of an institutional protocol implementing an extended postoperative oral TXA regimen received an additional 1.95-gram dose of oral TXA starting on the day of surgery and continued for three days postoperatively. Patient-reported outcome measures, hospital lengths of stay (LOSs), postoperative complications, 90-day readmissions, and primary TJA-related emergency department visits were compared between the oral TXA group and a historical cohort. All patients included in the analysis had a minimum follow-up of three months. A total of 312 patients were included (153 in the oral TXA group and 159 historical controls). Baseline demographics and preoperative Hip Disability and Osteoarthritis Outcome/Knee Injury and Osteoarthritis Outcome scores were comparable between groups. RESULTS: Extended TXA use was associated with significantly greater improvement in patient-reported outcome measures (change of 27.7 versus a change of 18.1; P < 0.001) and a significant reduction in TJA-related emergency department visits (odds ratio 0.11; 95% confidence interval 0.02 to 0.49; P = 0.007). There were no significant differences in LOS, 90-day readmissions, or postoperative complications, including infection or thromboembolic events (all P > 0.05). CONCLUSIONS: In this retrospective cohort of primary THA and TKA patients, the use of oral TXA for three days postoperatively was associated with improved early patient-reported function without an increase in complications or LOSs.
引用
- Thamer S, Price S, Brinkman N, et al. Improved Patient-Reported Outcomes With Extended Oral Tranexamic Acid Following Total Hip and Knee Arthroplasty. J Arthroplasty. 2026. PMID: 41956873. doi:10.1016/j.arth.2026.03.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。